Healthcare Perspectives

Metabolic dysfunction-associated steatotic liver disease (MASLD), also known as fatty liver disease, is a chronic liver condition that affects nearly 1 in 3 people worldwide. It is closely linked to obesity, type 2 diabetes, and metabolic syndrome. Unchecked, it can progress to a more severe form of disease called Metabolic Dysfunction-Associated Steatohepatitis (MASH).

Prognosticating the risk of disease progression in MASLD and MASH has traditionally involved liver biopsy. Recently, increasing evidence is suggesting that non-invasive options, for example, imaging examinations along with blood tests that assess likelihood of disease progression such as the Enhanced Liver Fibrosis (ELF) Test, may effectively reduce the need for the more invasive alternative. Key experts in MASLD and MASH share their perspectives about how clinical evidence supports a shift in the way patients  could be evaluated.

Host Matt Gee, Director of collaborations and external engagement at Siemens Healthineers, is joined by:

• Prof. William Rosenberg, Deputy Director of the Institute for Liver and Digestive Health at University College London
• Dr. Veronica Miller, Director of the Forum for Collaborative Research at the University of California, Berkeley School of Public Health
• Dr. Arun Sanyal, Professor of Medicine, Physiology, and Molecular Pathology in the Division of Gastroenterology at Virginia Commonwealth University 
• Dr. Michelle Long, International Medical Vice President of Metabolic Dysfunction-Associated Steatohepatitis at Novo Nordisk and Associate Professor in the Section of Gastroenterology and Hepatology at Boston University